The potassium-channel syndrome: does it exist?
Loke
Yoon K
YK
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ, UK. Y.Loke@uea.ac.uk <Y.Loke@uea.ac.uk>
D000255:Adenosine Triphosphate / Q000378:metabolism; D016638:Critical Illness; D016572:Cyclosporine / Q000009:adverse effects; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007530:Isoflurane / Q000009:adverse effects; D020108:Nicorandil / Q000009:adverse effects; D011188:Potassium / Q000097:blood; D026902:Potassium Channel Blockers / Q000627:therapeutic use; D015221:Potassium Channels / Q000187:drug effects* / Q000378:metabolism; D013577:Syndrome; D014664:Vasodilation
D026902:Potassium Channel Blockers; D015221:Potassium Channels; D020108:Nicorandil; D016572:Cyclosporine; D000255:Adenosine Triphosphate; D007530:Isoflurane; D011188:Potassium; D005905:Glyburide